ARA-290
About
About ARA-290
ARA-290 is a synthetic 11-amino-acid peptide that selectively activates the innate repair receptor (a heterodimer of the EPO receptor and beta common receptor) without erythropoietic effects, providing neuroprotection, anti-inflammatory, and tissue-repair actions. It has completed Phase II trials for neuropathic pain in sarcoidosis and is being studied for small fiber neuropathy, diabetic neuropathy, and inflammatory conditions. It represents a novel approach to harnessing erythropoietin's tissue-protective properties without its blood-thickening risks.
Science
Mechanism of Action
Selectively binds the heteromeric innate repair receptor (IRR) composed of EPOR and CD131 (βcR), activating anti-apoptotic, anti-inflammatory, and regenerative intracellular pathways in neurons, immune cells, and tissue progenitor cells without stimulating erythropoiesis.
Dosing
Typical Protocol
4 mg subcutaneous injection once daily for 28 days in clinical trials; compounded versions used off-label for neuropathy.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer ARA-290 — with trust scores, legal credentials, and pricing transparency.